Drugs / CD4^LVFOXP3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05241444 | Mar 2022 → Feb 2027 expected | immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome | Bacchetta, Rosa, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4^LVFOXP3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05241444 ↗ |
| Action | Restore | “Treatment with CD4^LVFOXP3 is expected to replace the defective Treg cells of the participants, and restore control of the immune system” NCT05241444 ↗ |
| Modality | Cell therapy | “Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer” NCT05241444 ↗ |
| Route | Other | “Infusion of autologous CD4+ T cells” NCT05241444 ↗ |